%0 Journal Article
%T High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement.
%A De Tavernier E
%A Detalle L
%A Morizzo E
%A Roobrouck A
%A De Taeye S
%A Rieger M
%A Verhaeghe T
%A Correia A
%A Van Hegelsom R
%A Figueirido R
%A Noens J
%A Steffensen S
%A Stöhr T
%A Van de Velde W
%A Depla E
%A Dombrecht B
%J J Biol Chem
%V 291
%N 29
%D 07 2016 15
%M 27226529
暂无%R 10.1074/jbc.M115.684241
%X Improving potencies through concomitant blockage of multiple epitopes and avid binding by fusing multiple (different) monovalent Nanobody building blocks via linker sequences into one multivalent polypeptide chain is an elegant alternative to affinity maturation. We explored a large and random formatting library of bivalent (combinations of two identical) and biparatopic (combinations of two different) Nanobodies for functional blockade of Pseudomonas aeruginosa PcrV. PcrV is an essential part of the P. aeruginosa type III secretion system (T3SS), and its oligomeric nature allows for multiple complex binding and blocking options. The library screening yielded a large number of promising biparatopic lead candidates, revealing significant (and non-trivial) preferences in terms of Nanobody building block and epitope bin combinations and orientations. Excellent potencies were confirmed upon further characterization in two different P. aeruginosa T3SS-mediated cytotoxicity assays. Three biparatopic Nanobodies were evaluated in a lethal mouse P. aeruginosa challenge pneumonia model, conferring 100% survival upon prophylactic administration and reducing lung P. aeruginosa burden by up to 2 logs. At very low doses, they protected the mice from P. aeruginosa infection-related changes in lung histology, myeloperoxidase production, and lung weight. Importantly, the most potent Nanobody still conferred protection after therapeutic administration up to 24 h post-infection. The concept of screening such formatting libraries for potency improvement is applicable to other targets and biological therapeutic platforms.